A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor

Date de début de l'étude : 1 novembre 1995

DISEASE CHARACTERISTICS: One of the following diagnoses: Acute myelogenous leukemia (AML) meeting 1 of the following conditions: Failed to achieve first remission after an intensive induction regimen containing an anthracycline and cytarabine In second remission and not enrolled in a protocol for autologous bone marrow transplantation Failed to achieve or sustain second remission In first remission but at high risk of relapse because of 1 of the following factors: High-risk cytogenetic features (monosomy 7,5q-, trisomy 8, or t(9;22)) AML secondary to treatment of a prior malignancy and without good-risk cytogenetic features of t(8;21), t(15;17), or inv 16 AML secondary to myelodysplastic disease Acute lymphocytic leukemia (ALL) meeting 1 of the following conditions: In second remission with initial relapse occurring within 2 years of diagnosis In first complete remission with high-risk cytogenetics (t(9;22) or t(4;11)) In third or subsequent remission Failed to achieve or sustain a second remission Chronic myelogenous leukemia (CML) in first or second chronic phase or accelerated phase Stage IV lymphoblastic lymphoma not in first remission or that failed to achieve a remission within the first 4 weeks of induction therapy Juvenile CML Myelodysplastic syndrome Severe aplastic anemia unresponsive to anti-thymocyte globulin or cyclosporine No CNS or skin involvement with leukemia No requirement for mediastinal irradiation No healthy, HLA-identical related donor of at least 1 year of age or matched unrelated donor available within 4-6 months Availability of a healthy, 1-3 HLA-A, -B, and -DR mismatched related donor Willing and able to undergo general anesthesia for marrow donation and a 5-day course of filgrastim (G-CSF) with 2 daily leukaphereses PATIENT CHARACTERISTICS: Age: Under 50 (50 and over allowed on a case-by-case basis) Performance status: Age 16 and over: Karnofsky 70-100% Under age 16: Lansky 50-100% Hematopoietic: Not specified Hepatic: Bilirubin less than 2.0 mg/dL (in the absence of liver involvement) AST less than twice normal (in the absence of liver involvement) Renal: Creatinine normal OR Creatinine clearance greater than 60 mL/min Cardiovascular: Asymptomatic or LVEF greater than 50% at rest, with improvement during exercise Pulmonary: Asymptomatic or DLCO greater than 50% predicted (corrected for hemoglobin) Other: No known hypersensitivity to mouse protein or chicken egg products No active viral, bacterial, or fungal infection HIV-1, HIV-2, HTLV-1, and HTLV-2 negative No other concurrent medical condition that would preclude transplantation Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specified Radiotherapy See Disease Characteristics Surgery See Disease Characteristics